RxDoctor Payments Data

Isha Shah, MD

Rheumatology · Warwick, RINPI 1326490699

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Novartis at 30.7% of the total. Reporting peaked in 2021 at $338 and has fallen 87.0% since, to $44 in 2025. That places this record below the midpoint for rheumatology clinicians in RI, where the typical reported total is $1,983.

$1,089in general payments, 2019–2025

Across 39 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$335
  • AbbVie$328
  • Amgen$199
  • AstraZeneca$189
  • E.r. Squibb & Sons, L.L.C.$21
  • GSK$17

What the payments were for

  • Food & beverage$1,07799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis5$335
AbbVie20$328
Amgen10$199
AstraZeneca2$189
E.r. Squibb & Sons, L.L.C.1$21
GSK1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,089 in reported general payments places this provider in the 40th percentile of 22 rheumatology providers in Rhode Island.

See all rheumatology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$43,267
Medicare patients
172
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept90$640,341
Humira(Cf) PenAdalimumab63$451,428
Humira PenAdalimumab16$108,157
ForteoTeriparatide22$89,310
ProliaDenosumab15$25,643
Hydroxychloroquine Sulfate309$13,661
MethotrexateMethotrexate Sodium286$6,042
Pilocarpine Hcl50$4,428
Prednisone353$3,921
Colchicine55$3,013
Cevimeline Hcl14$2,343
Leflunomide26$1,777
Alendronate Sodium145$1,774
Allopurinol162$1,589
Celecoxib63$1,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$199$25,64315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 22 rheumatology providers in Rhode Island.

Other rheumatology in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →